Selvan Senthamil R, Dowling John P, Kelly William K, Lin Jianqing
Division of Solid Tumor, Department of Medical Oncology, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107, USA.
Curr Cancer Drug Targets. 2016;16(9):755-764. doi: 10.2174/1568009615666151030102250.
Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
吲哚胺2,3-双加氧酶（IDO）是一种含血红素的氧化还原酶，催化非膳食色氨酸分解的起始和限速步骤。本综述讨论了IDO的生物学特性和免疫调节作用，重点关注其与免疫细胞的相互作用及其在临床上的潜在治疗靶点。已发现IDO在多种生理和病理环境中是免疫反应的核心调节因子，主要作为一种多方面的负反馈机制来自我调节免疫反应。IDO被认为是癌症的治疗靶点，目前正在积极研究将IDO抑制剂作为单一药物或与其他治疗方式联合使用。
